Entries by Louise Mason

Key Appointments Strengthen Mission Therapeutics’ Senior Management Team

CAMBRIDGE, UK– 4 August 2020 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced the promotions of Dr Paul Thompson to CSO and Dr Nick Edmunds to CTO with immediate effect. Dr Paul Thompson (CSO) In his new role, Dr Thompson assumes responsibility for Mission’s […]

Mission and Imperial College London Report Potent and Selective Probe for Deubiquitylating Enzyme UCHL1

LONDON AND CAMBRIDGE, UK – 7 July 2020 – Working in close collaboration, scientists from the Tate Group, Imperial College London, and drug discovery and development company, Mission Therapeutics (“Mission”), have discovered the first exquisitely selective probe for a deubiquitylating enzyme (DUB). The research has been published in the leading peer-reviewed Journal of the American […]

Mission Raises $15m and Expands its Relationship with Pfizer

CAMBRIDGE, UK– 6 July 2020 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that it has raised $15m (£12m) in equity investment. The round was led by existing investor Pfizer Ventures, the venture capital arm of Pfizer Inc. (“Pfizer”)(NYSE: PFE). Mission and Pfizer Inc. […]

Mission and AbbVie’s Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Milestone

CAMBRIDGE, UK – 3 December 2019 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), and AbbVie (“AbbVie”)(NYSE: ABBV), a global, research-driven biopharmaceutical company, today announced the identification of several DUBs as potential drug targets in their Alzheimer’s and Parkinson’s R&D collaboration. AbbVie has nominated the panel […]

Mission Therapeutics’ Collaboration with AbbVie Nominated for Scrip Best Partnership Alliance Award

CAMBRIDGE, UK – 16 September 2019 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), announced today that its collaboration with research-based global biopharmaceutical company, AbbVie (“AbbVie”)(NYSE: ABBV), has been shortlisted for the 2019 Scrip Best Partnership Alliance Award. Mission and AbbVie are working together in the […]

Dr. James Summers Appointed to Mission Therapeutics’ Board of Directors

CAMBRIDGE, UK – 1 May 2019 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), today announced the appointment of Dr. James Summers as an independent member to its Board of Directors, with immediate effect. Dr. Summers brings over […]

Dr Nick Edmunds Appointed to VP, Head of DUB Discovery

CAMBRIDGE, UK – 3 December 2018 –Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Nick Edmunds as Vice President, Head of DUB Discovery, with immediate effect. Dr Edmunds has over 15 years’ pharmaceutical industry experience and a […]

Mission Therapeutics and AbbVie sign DUBs Collaboration in Alzheimer’s and Parkinson’s Disease

Collaboration combines Mission’s unique science, chemistry and proprietary enzyme platform with AbbVie’s strong neurodegenerative disease research, development and commercialisation capabilities CAMBRIDGE, UK and NORTH CHICAGO, ILL, USA – 15th November 2018 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) and AbbVie (“AbbVie”)(NYSE: ABBV), a research-based global […]

Mission Therapeutics Strengthens Clinical Development Team with Appointment of Dr Judit Molnar as Senior Director, Translational Medicine

CAMBRIDGE, UK – 4 September 2018 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat mitochondrial diseases, fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Judit Molnar, MD, PhD to Senior Director of Translational Medicine with immediate effect. Judit has over ten […]